Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages

  Vizzini, Giovanni ^a   Gruttadauria, Salvatore ^a,b   Volpes, Riccardo ^a   D'Antoni, Adele ^a   Pietrosi, Giada ^a   Filig, Daniela ^a   Petridis, Ioannis ^a   Pagano, Duilio ^a   Tuzzolino, Fabio ^a   Santonocito, M Maria ^c   Gridelli, Bruno ^a,b  

^a MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c School of Medicine   (Italy)

Author keywords

HBcAb positive liver graft; Hepatitis B infection; Lamivudine; Liver transplantation; Outcome

Indexed keywords

ADEFOVIR; BASILIXIMAB; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DE NOVO HEPATITIS B; DONOR; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; MONOPROPHYLAXIS; MONOTHERAPY; MULTIPLE ORGAN FAILURE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CADAVER; CHILD; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 79551704913     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01329.x     Document Type: Article

References (19)

1. Gruttadauria S, Vizzini G, Biondo D et al. Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience. Liver Transpl 2008: 14: 220.
2. Pruett TL. Editorial response: de novo HBV infections after liver transplantation. Liver Transpl Surg 1998: 4: 182.
3. Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006: 45: 127.
4. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001: 7: 51.
5. Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001: 6: 513.
6. Prakoso E, Strasser SI, Koorey DJ et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core antibody-positive donors. Clin Transplant 2006: 20: 369.
7. Gruttadauria S, Cintorino D, Mandala' L et al. Acceptance of marginal liver donors increases the volume of liver transplant: early results of a single-center experience. Transplant Proc 2005: 37: 2567.
8. Yu L, Koespell T, Manhart L et al. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009: 15: 1343.
9. Chen YS, Wang CC, De Villa VH et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002: 16: 405.
10. De Villa VH, Chen YS, Chen CL. Hepatitis B core antibody positive grafts: recipient's risk. Transplantation 2003: 75(Suppl): S49.
11. Prieto M, Rubi'n A, Berenguer M et al. Use of grafts from HBsAg-negative HBcAb-positive donors in liver transplantation: long-term results of a selective assignation strategy. Hepatology 2008: 48(4 Suppl): 576A.
12. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993: 329: 1842.
13. Roque-Afonso AM, Feray C, Samuel D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002: 50: 95.
14. Dodson SF, Bonham CA, Geller DA et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999: 68: 1058.
15. Holt D, Thomas R, Van Thiel D et al. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002: 137: 572.
16. Jain A, Orloff M, Abt P et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005: 37: 3187.
17. Suehiro T, Shimada M, Kishikawa K et al. Prevention of hepatitis B virus infection from hepatitis B core antibody positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005: 25: 1169.
18. Yen RD, Bonatti H, Mendez J et al. Case report of lamivudine resistant hepatitis B virus infection post-liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006: 6(Pt 1): 1077.
19. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003: 125: 1714.